Gilman Michael sold $137K of SRRK

Gilman Michael sold 2,544 shares of Scholar Rock Holding Corp (SRRK) at an average of $53.88 ($53.54–$54.81, $0.14M total) across 3 trades on 2026-07-01 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Gilman Michael
Published Jul 6, 2026, 4:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 6, 2026, 7:49 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$SRRK
Neutral
medium confidence
Mentioned
$SRRK
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$SRRKNeutralLow
01

Why it matters

The disclosure updates the record of insider activity but does not include new company fundamentals such as guidance, trial results, contracts, or regulatory actions.

02

Market read

Primarily a sentiment/positioning datapoint for SRRK, with limited expected impact given the 10b5-1 structure.

03

What to watch

The article provides sale size and weighted prices but no context on total holdings, future planned sales, or whether other insiders have concurrent activity.

Relevance 3/10Novelty 3/10Timing: filed 2026-07-06 for trades dated 2026-07-01

Background

This is an SEC Form 4 insider transaction disclosure for Scholar Rock Holding Corp, reported as an open-market sale by a director under a pre-arranged 10b5-1 plan.

Company-level read

Ticker impact

$SRRKNeutralMedium confidence
Context

Form 4 shows director Gilman Michael sold 2,544 SRRK shares in open-market trades under a pre-arranged 10b5-1 plan.

Expected impact

Likely minimal, though it can add slight overhang sentiment if traders focus on insider selling.

Evidence & confidence

The transaction is disclosed via SEC Form 4 and explicitly tied to a pre-arranged 10b5-1 plan, which typically reduces interpretive weight versus discretionary selling.

Market effects

No clear sector read-through from a single director 10b5-1 sale.

None indicated.

None indicated.

Counterpoint

Traders may overreact to insider sales; 10b5-1 plans are often used to manage liquidity and taxes rather than signal bearish views.

Key entities

  • Scholar Rock Holding Corp

    Subject of the Form 4 insider sale disclosure.

  • Gilman Michael

    Director who sold SRRK shares under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$SRRKMedAI 8/10

Scholar Rock (SRRK) Q3 2026 Earnings Call Transcript

Scholar Rock (SRRK) reported Q3 2026 earnings, highlighting FDA approval of ISEMBYLD for SMA, a $205M deal for a priority review voucher, and progress in Japan and Phase II FORGE study. ISEMBYLD showed a 2.2-point motor function improvement in trials, with strong early launch demand. The company reported $0.6M in ISEMBYLD revenue and $413.6M in cash, with no immediate need for equity offering.

$SRRKLow

What Scholar Rock (SRRK) Said on Its Q3 Earnings Call

Scholar Rock (SRRK) reported Q3 earnings, noting no demand impact from a bone fracture warning. The company resubmitted its European marketing application for apitegromab, expecting a decision in early 2027. It anticipates a 2027 launch in Japan and Germany. Operating expenses were $106.6M, with $413.6M in cash. SRRK sold a priority review voucher for $205M and has access to an additional $150M under its debt facility.

$SRRKHighAI 8/10

Raymond James reiterates Strong Buy on Scholar Rock stock after Q3 results

Raymond James maintained a Strong Buy rating and $72.00 price target for Scholar Rock (NASDAQ: SRRK) after its Q3 2026 results. The stock is up 17% this week and 76% over the past year. Scholar Rock reported its first product revenues for ISEMBYLD, which received FDA approval in September 2026. The company's EPS beat estimates but revenue missed expectations, falling 60.14% short of forecasts.